Articles

P.11 Outcome and relapse pattern between squamous cell and adenocarcinoma of the cervix

BJMO - 2017, issue 3, february 2017

K. Couvreur , K. Vandecasteele MD, PhD, P. Tummers , A. Makar , R. Van Den Broecke , H. Denys MD, PhD

Read more

The changing role of the axillary dissection in the treatment of breast cancer

BJMO - volume 6, issue 3, june 2012

A. Smeets MD, PhD, B. Carly MD, V. Cocquyt MD, PhD, M. Vanhoeij , C. Bourgain MD, PhD, E. Lifrange MD, PhD, G. Villeirs MD, PhD, M. De Ridder MD, PhD, M. Drijkoningen MD, PhD, J. Lamote , R. Van Den Broecke , M. Voordeckers , J. De Grève MD, PhD, P. Neven MD, PhD, M.R. Christiaens

The aim of this article is to highlight the recent changes in the surgical approach of the axilla in breast cancer patients. Axillary staging is dominated by the sentinel lymph node (SLN) biopsy, which is now widely practiced in clinically node negative patients. Most authors believe a SLN biopsy may even be performed in patients with a large or multifocal tumour, before neo-adjuvant systemic therapy, during pregnancy, after prior excisional biopsy and after prior mantle field radiotherapy of the breast. Intra-operative assessment of the SLN is recommended as it can identify half of all positive lymph nodes. It is generally accepted that it is safe to omit an axillary lymph node dissection (ALND) in patients with a negative SLN or with only isolated tumour cells (<0.2 mm) in the SLN. Moreover, in a subset of patients with a micro-/macrometastasis in the SLN it might not be necessary to perform a completion of ALND. We suggest to accept the option of omitting completion of ALND in frail patients with a positive sentinel lymph node on final pathology OR in these patients with, on final pathology, one or two positive SLNs AND a grade I or II tumour smaller than 4 cm AND adjuvant radiotherapy on the whole breast or chest wall. In conclusion, an increasingly tailored surgical approach is guiding the management of the axilla for women with early breast cancer. (BELG J MED ONCOL 2012;6:87–95)

Read more